Septicemia is a disease caused by the spread of bacteria and their toxins in the bloodstream. Also called blood poisoning and toxemia.
Anthrax, septicemia and meningitis are some of the planet's most deadly infections. In part because doctors lack basic insights to prevent and cure diseases caused by so called Gram-positive bacteria. Now, a chemist from the University of Copenhagen has revealed the mechanism behind these deadly infections.
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced positive top-line results from the recently completed Phase 2 studies of its CXA-201 and CB-183,315 antibiotic pipeline candidates. CXA-201 was studied for the treatment of complicated intra-abdominal infections (cIAI) in adults.
Indiana Gov. Mitch Daniels, a Republican considering a run for president, signed legislation Tuesday to bar Planned Parenthood from receiving federal funding in his state, a move widely seen as a bid to woo influential social conservatives. Planned Parenthood of Indiana and the American Civil Liberties Union went to court to try to block the measure from taking effect.
A study performed by University of Kentucky researchers shows promise for the use of azithromycin in treating Ureaplasma-colonized or infected premature infants to prevent bronchopulmonary dysplasia (BPD).
A study performed by University of Kentucky researchers shows promise for the use of azithromycin in treating Ureaplasma-colonized or infected premature infants to prevent bronchopulmonary dysplasia.
The February 19, 2011 article written by reporters from California Watch repeats SEIU's allegation that Prime Healthcare hospitals use a diagnosis of malnutrition to increase reimbursement.
Prime Healthcare Services (PHS), the largest for-profit hospital system in California and the only for-profit system among Thomson Reuters' Top 10 Health Systems in 2009, announced today that it has been the victim of an extortion campaign by the Service Employees International Union – United Healthcare Workers West (SEIU) over the past year.
Merck today announced that the New Drug Application (NDA) for the Company's investigational extended-release formulation of JANUMET for type 2 diabetes has been accepted for standard review by the U.S. Food and Drug Administration (FDA). The Company is also moving forward as planned with regulatory filings in countries outside the United States.
The Penn Transplant Institute, the Department of Orthopaedic Surgery and the Division of Plastic Surgery at the Hospital of the University of Pennsylvania (HUP) have collaborated to form the Penn Hand Transplant Program.
Hospital charges for the most expensive patient stays at U.S. hospitals in 2008 averaged about $18,000 per day, according to the Agency for Healthcare Research and Quality. These patients were most likely to be in the hospital for treatment of septicemia, or blood infection, hardening of the arteries, and heart attacks.
The Los Angeles Times reports that state and federal investigators are trying to determine whether "a serious health problem or multimillion-dollar Medicare fraud" is behind a reported spike in blood poisoning cases at hospitals operated by Prime Healthcare Services, "a Southern California hospital chain known for aggressive billing practices and cost-cutting."
Today's early morning highlights from major news organizations look at a probe of a California hospital chain, the effect that the governors' races around the country will have on the federal health law and a review of prescription purchases that shows more Americans are foregoing their medicines.
Treating intensive care patients who develop life-threatening bacterial infections, or septicemia, with insulin potentially could reduce their chances of succumbing to the infection, if results of a new preliminary study can be replicated in a larger study.
Adults who developed health care-associated infections (HAIs) due to medical or surgical care while in the hospital in 2007 had to stay an average of 19 days longer than adults who didn't develop an infection, (24 days versus 5 days), according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
Novo Nordisk announced today that the U.S. Food and Drug Administration has approved NovoSeven® RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) in an 8 mg vial size, making the hemophilia A or B with inhibitors treatment available in 1, 2, 5 and 8 mg vials. The 8 mg vial allows a rapid initiation and administration of this medication for those patients who need a larger dose. In addition, FDA has also approved the extension of shelf life for all vial sizes from 24 months to 36 months at room temperature (at or below 77 degrees Fahrenheit).
The U.S. Department of Justice, in an action initiated by the U.S. Food and Drug Administration, is seeking a permanent injunction against NY Gourmet Salads, Inc., a processor of ready-to-eat deli salads, seafood salads, and cream cheeses in Brooklyn, N.Y., and Leonard F. Spada, the company's president.
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced the enrollment of the first patient in a Phase 2 study with CXA-201. This multicenter, double-blind, randomized, study will compare the safety and efficacy of intravenous CXA-201 with an active comparator in patients with complicated intra-abdominal Infections (cIAI). This international study is expected to enroll 120 patients.
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that the recently-completed Phase 2 study of CXA-101, a novel cephalosporin, compared to ceftazidime for the treatment of complicated urinary tract infections (cUTI) in adults met its study objectives.
New data were presented at the American Diabetes Association 70th Annual Scientific Sessions from a study comparing JANUMET (sitagliptin/metformin) to pioglitazone. In this study, JANUMET resulted in significantly greater blood sugar reductions in patients with type 2 diabetes compared with pioglitazone.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Aztreonam for Injection, USP in two dosage strengths. Aztreonam is therapeutically equivalent to the reference-listed drug Azactam, which is marketed by Bristol-Myers Squibb.